IndieBio is the life sciences accelerator platform within SOSV and operates primarily out of San Francisco and New York. It focuses on very early-stage companies at the intersection of biology and engineering and typically provides pre-seed funding alongside structured accelerator support. Its model is designed for founders building technically complex companies before they are ready for traditional institutional scale rounds.

A major differentiator is its provision of wet lab access, operational support, and intensive mentorship. Its portfolio includes companies relevant to neurotechnology, such as those working in spinal stimulation and portable imaging. IndieBio is especially valuable for founders building from first principles in bioengineering, medtech, and platform biology.

The program invests globally, although it is anchored in the US startup ecosystem. For neurotech, it is particularly relevant to pre-seed founders developing biologically informed devices, imaging platforms, or other neuroengineering tools that need both lab infrastructure and early company-building support. It is best viewed as an accelerator-first entry point into venture-backed neurotech.